Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 20Carcinoma, Renal Cell 11Prostatic Neoplasms 8Uveal Melanoma 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 5Myelodysplastic Syndromes 5Clear-cell metastatic renal cell carcinoma 5Triple Negative Breast Neoplasms 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Brain Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Hematologic Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2

Interventions

Paclitaxel 42Carboplatin 35pembrolizumab 25Surveys and Questionnaires 23Letrozole 15Radiotherapy 14Megestrol Acetate 14Blood Specimen Collection 14Bevacizumab 13olaparib 12Metformin 12dostarlimab 10Indocyanine Green 10durvalumab 9Observation 9Medroxyprogesterone Acetate 9Cisplatin 9lenvatinib 8atezolizumab 8Early Intervention, Educational 8Counseling 8niraparib 7Sentinel Lymph Node Biopsy 7Radiation 7Methods 7Magnetic Resonance Spectroscopy 7Lymph Node Excision 7Hysterectomy 7Everolimus 7abemaciclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Endometrial Neoplasms × CTLA-4 Antigen × Clear all
NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

M.D. Anderson Cancer Center

Phase 1 Completed
26 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡